IDO takes a blow

Nature Reviews Drug Discovery 17, 307 (2018). doi:10.1038/nrd.2018.67 Author: Asher Mullard Incyte's epacadostat and Merck & Co's pembrolizumab failed in a phase III combination study in unresectable and metastatic melanoma, the companies reported in April, dealing a major blow to hopes for the would-be first-in-class IDO inhibitor.Whereas most of the immuno-oncology research to date
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research